precision medicine

Conference Coverage

2015 American Society of Hematology Annual Meeting & Exposition

02/16/2016

JCP Editors

In April of 1958, the American Society of Hematology (ASH) was formed in Atlantic City, NJ, when 300 hematologists gathered to share their insights regarding blood diseases. Today, ASH is one of the world’s largest...

In...

02/16/2016

Journal of Clinical Pathways

Precision Medicine: Using Genetics to Drive Treatment Decisions

02/15/2016

JCP Editors

The emphasis on precision medicine continues as health care providers discover the value of using information about a patient’s particular disease to inform treatment approaches. Genetic testing and personalized...

The...

02/15/2016

Journal of Clinical Pathways

Research in Review

Predictive Biomarker for Panitumumab Therapy Effectiveness in Patients With Colorectal Cancer

02/12/2016

JCP Editors

Expression of epidermal growth factor receptor ligands epiregulin (EREG) and amphiregulin (AREG) may help determine which patients with colorectal cancer are the most likely to benefit from panitumumab therapy. The...

...

02/12/2016

Journal of Clinical Pathways

Research in Review

New Assay More Sensitive for Identifying CML Remission Likely to Relapse

02/10/2016

JCP Editors

A new personalized DNA-based digital polymerase chain reaction (dPCR) assay could help determine which patients with chronic myeloid leukemia (CML) are more likely to relapse while in molecular remission. Advances...

A new...

02/10/2016

Journal of Clinical Pathways

Research in Review

Intense Tumor Lymphocytic Infiltration Predicts Improved Survival in Patients With NSCLC

02/05/2016

JCP Editors

A new study, published in the Journal of Clinical Oncology, has found that a greater presence of tumor lymphocytic infiltration (TLI) may be associated with a greater likelihood of survival in patients with non-small...

A new...

02/05/2016

Journal of Clinical Pathways

Research in Review

Higher Doses of Radiation Therapy Effective and Safe for Patients With NSCLC

02/02/2016

JCP Editors

Precision hypofractionated radiation therapy (RT) may be a potent alternative for patients with non-small cell lung cancer (NSCLC) who cannot receive chemotherapy due to the potential for severe side...

...

02/02/2016

Journal of Clinical Pathways

Research in Review

Prognostic Value of Colon Cancer Biomarkers Depends on DNA Mismatch Repair Status

01/25/2016

JCP Editors

Mutations of the BRAF and KRAS genes may be associated with worse outcomes in certain patients with colon cancer, according to a new study. The use of BRAF and KRAS as prognostic indicators in colon cancer has been...

...

01/25/2016

Journal of Clinical Pathways

Research in Review

Dacomitinib Comparable to Erlotinib in Patients with EGFR+ NSCLC

01/18/2016

JCP Editors

Dacomitinib may be comparable to erlotinib in treating non-small cell lung cancer (NSCLC), specifically in patients that are positive for the epidermal growth factor receptor (EGFR) mutation. Dacomitinib, an...

...

01/18/2016

Journal of Clinical Pathways

Research in Review

Selection Criteria Barring Access to Clinical Trials for NSCLC Patients

01/15/2016

JCP Editors

Clinical trials for non–small cell lung cancer (NSCLC) are increasingly demanding tumor samples or research biopsies, which may bar participation and delay treatment for patients, a new study finds. The need for...

...

01/15/2016

Journal of Clinical Pathways

Research in Review

Effectiveness of Drug for First-Line Treatment of EGFR+ Non-Small Cell Lung Cancer Supported by New Study

01/08/2016

JCP Editors

First-line treatment with erlotinib for epidermal growth factor receptor (EGFR) mutation–positive non-small cell lung cancer (NSCLC) patients may have benefits even after disease progresses, a new study...

...

01/08/2016

Journal of Clinical Pathways